Anthem (NASDAQ:ANTX) Announces Earnings Results

Anthem (NASDAQ:ANTX) posted its quarterly earnings data on Monday. The company reported ($0.17) earnings per share for the quarter, FiscalAI reports.

Here are the key takeaways from Anthem’s conference call:

• AN2 received FDA clearance to begin its Phase II polycythemia vera (PV) trial and expects to dose the first patient this year. The 75-patient study will test three doses; initial sentinel-cohort safety data are expected in Q1, with broader efficacy updates potentially starting around mid-2027. The drug has a substantial prior safety and hematocrit-effect database, but has not yet been tested in PV patients.
• The company expects to start a 60-patient, two-dose Phase II Chagas study in Bolivia in early 2027, with a readout targeted for the second half of the year. AN2 cited positive monkey studies and the potential for a priority review voucher if successful, while emphasizing the disease’s unmet need and an estimated 300,000-plus U.S. cases.
• AN2 is advancing epetraborole for M. abscessus lung disease, where it says an oral treatment could improve on prolonged IV antibiotic regimens and its preclinical profile supports testing in treatment-naive patients. This program follows the company’s Phase III miss in treatment-refractory MAC; management attributed that result to a particularly difficult patient population, but the new program’s clinical efficacy remains unproven.
• Management described a broad early-stage pipeline, including a hypophosphatasia program expected to enter Phase I next year and preclinical oncology programs such as a pan-mutant PI3K inhibitor. The PI3K program remains in research, and AN2 said it is still seeking a suitable compound before developing it further or pursuing a strategic partner.

Anthem Stock Performance

Shares of ANTX opened at $4.00 on Tuesday. Anthem has a one year low of $1.00 and a one year high of $7.19. The company’s fifty day moving average price is $4.71 and its 200 day moving average price is $4.12.

Wall Street Analyst Weigh In

ANTX has been the topic of a number of recent analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Anthem in a research note on Friday, October 2nd. Guggenheim began coverage on Anthem in a report on Monday, July 20th. They issued a “buy” rating and a $9.00 target price for the company. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $9.00.

Insiders Place Their Bets

In other Anthem news, Director Robin Shane Readnour sold 35,402 shares of the company’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $6.01, for a total transaction of $212,766.02. Following the completion of the sale, the director directly owned 565,592 shares in the company, valued at $3,399,207.92. This represents a 5.89% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last three months, insiders have sold 55,727 shares of company stock worth $330,207. 22.61% of the stock is owned by insiders.

Hedge Funds Weigh In On Anthem

Several large investors have recently made changes to their positions in the business. Vivo Capital LLC bought a new position in Anthem in the 1st quarter worth approximately $10,785,000. Seven Fleet Capital Management LP bought a new stake in shares of Anthem in the first quarter valued at approximately $683,000. Commodore Capital LP acquired a new stake in shares of Anthem in the first quarter worth $7,981,000. Spruce Street Capital LP acquired a new stake in shares of Anthem in the first quarter worth $5,576,000. Finally, Ally Bridge Group NY LLC bought a new position in Anthem during the first quarter worth $1,800,000. Institutional investors and hedge funds own 90.47% of the company’s stock.

About Anthem

An2 Therapeutics, Inc is a clinical-stage biopharmaceutical company that traded on the Nasdaq under the symbol ANTX. The company focused on developing novel treatments for serious infectious diseases, with its lead candidate, epetraborole, designed as an oral therapy for pulmonary disease caused by nontuberculous mycobacteria (NTM).

Epetraborole was evaluated in clinical studies involving patients with refractory Mycobacterium avium complex pulmonary disease, a difficult-to-treat infection that primarily affects the lungs.